About teva pharmaceutical industries ltd. - TEVA
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
TEVA At a Glance
Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a Street
Tel Aviv, Tel Aviv 6944020
| Phone | 972-3-914-8213 | Revenue | 17.32B | |
| Industry | Pharmaceuticals: Generic | Net Income | 1.41B | |
| Sector | Health Technology | 2025 Sales Growth | 4.924% | |
| Fiscal Year-end | 12 / 2026 | Employees | 33,346 | |
| View SEC Filings |
TEVA Valuation
| P/E Current | 65.338 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 26.113 |
| Price to Sales Ratio | 2.125 |
| Price to Book Ratio | 4.603 |
| Price to Cash Flow Ratio | 12.86 |
| Enterprise Value to EBITDA | 10.06 |
| Enterprise Value to Sales | 2.915 |
| Total Debt to Enterprise Value | 0.341 |
TEVA Efficiency
| Revenue/Employee | 519,492.593 |
| Income Per Employee | 42,283.932 |
| Receivables Turnover | 4.672 |
| Total Asset Turnover | 0.433 |
TEVA Liquidity
| Current Ratio | 1.036 |
| Quick Ratio | 0.80 |
| Cash Ratio | 0.264 |
TEVA Profitability
| Gross Margin | 51.971 |
| Operating Margin | 23.189 |
| Pretax Margin | 7.06 |
| Net Margin | 8.139 |
| Return on Assets | 3.522 |
| Return on Equity | 21.23 |
| Return on Total Capital | 5.609 |
| Return on Invested Capital | 6.279 |
TEVA Capital Structure
| Total Debt to Total Equity | 217.775 |
| Total Debt to Total Capital | 68.531 |
| Total Debt to Total Assets | 42.274 |
| Long-Term Debt to Equity | 193.565 |
| Long-Term Debt to Total Capital | 60.913 |
Teva Pharmaceutical Industries Ltd. in the News
Stock futures trade mixed ahead of Fed decision
U.S. equity futures were pointing lower ahead of Wednesday's opening bell on Wall Street.